JP2011507862A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507862A5
JP2011507862A5 JP2010539519A JP2010539519A JP2011507862A5 JP 2011507862 A5 JP2011507862 A5 JP 2011507862A5 JP 2010539519 A JP2010539519 A JP 2010539519A JP 2010539519 A JP2010539519 A JP 2010539519A JP 2011507862 A5 JP2011507862 A5 JP 2011507862A5
Authority
JP
Japan
Prior art keywords
connexin
composition
polynucleotide
scar
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010539519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/014028 external-priority patent/WO2009085277A2/en
Publication of JP2011507862A publication Critical patent/JP2011507862A/ja
Publication of JP2011507862A5 publication Critical patent/JP2011507862A5/ja
Pending legal-status Critical Current

Links

JP2010539519A 2007-12-21 2008-12-22 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用 Pending JP2011507862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US887707P 2007-12-21 2007-12-21
PCT/US2008/014028 WO2009085277A2 (en) 2007-12-21 2008-12-22 Treatment of abnormal or excessive scars

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014248308A Division JP2015057431A (ja) 2007-12-21 2014-12-08 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用

Publications (2)

Publication Number Publication Date
JP2011507862A JP2011507862A (ja) 2011-03-10
JP2011507862A5 true JP2011507862A5 (enExample) 2013-04-25

Family

ID=40824960

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010539519A Pending JP2011507862A (ja) 2007-12-21 2008-12-22 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
JP2014248308A Pending JP2015057431A (ja) 2007-12-21 2014-12-08 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014248308A Pending JP2015057431A (ja) 2007-12-21 2014-12-08 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用

Country Status (7)

Country Link
US (1) US20110130710A1 (enExample)
EP (1) EP2252690A2 (enExample)
JP (2) JP2011507862A (enExample)
AU (1) AU2008343758A1 (enExample)
CA (1) CA2710388A1 (enExample)
WO (1) WO2009085277A2 (enExample)
ZA (1) ZA201005223B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
AU2008335718A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
US10576037B2 (en) * 2012-03-14 2020-03-03 MAM Holdings of West Florida, L.L.C. Compositions comprising placental collagen for use in wound healing
CN104736709A (zh) 2012-03-27 2015-06-24 科达治疗公司 基于钙粘蛋白调节的组合物和治疗
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
HK1247622A1 (zh) 2015-03-02 2018-09-28 180 Therapeutics Lp 利用il-33拮抗剂来治疗局部纤维化的方法
WO2016149194A1 (en) 2015-03-13 2016-09-22 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
WO2019005643A1 (en) * 2017-06-26 2019-01-03 Next Science IP Holdings Pty Ltd METHOD OF TREATING PATHOLOGIES OF COLLAGEN FIBERS
WO2019152110A1 (en) * 2018-01-31 2019-08-08 Kci Usa, Inc. Antimicrobial composition, dressing, dressing components, and method
EP4232157A4 (en) 2020-10-22 2024-08-28 Xequel Bio, Inc. PEPTIDE FORMULATIONS AND ASSOCIATED OPHTHALMIC USES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6566339B1 (en) * 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
IT1294967B1 (it) * 1996-10-09 1999-04-23 Ist Farmacoterapico It Spa Composizione immunogenica da tlp
WO1998021358A1 (en) * 1996-11-15 1998-05-22 University Of Massachusetts Huntingtin-related therapeutics and bioassay
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid
US6855505B2 (en) * 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
CA2361251C (en) * 1999-01-27 2011-03-08 David L. Becker Formulations comprising antisense nucleotides to connexins
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
US7186802B2 (en) * 2000-08-15 2007-03-06 Immunex Corporation Claudin polypeptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
JP5838017B2 (ja) * 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
JP5097891B2 (ja) * 2005-09-20 2012-12-12 株式会社ポーラファルマ 皮膚外用剤
JP5960944B2 (ja) * 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
EP2340309A2 (en) * 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters

Similar Documents

Publication Publication Date Title
Ouyang et al. Targeted delivery of hesperetin to cartilage attenuates osteoarthritis by bimodal imaging with Gd2 (CO3) 3@ PDA nanoparticles via TLR-2/NF-κB/Akt signaling
JP5736397B2 (ja) コネキシンに対するアンチセンスヌクレオチドを含む配合物
US20110130710A1 (en) Treatment of abnormal or excessive scars
JP2015518712A (ja) Ｍｅｃｐ２発現を調節するための組成物及び方法
JP2015523855A (ja) Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法
WO2011140285A2 (en) Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
JP2011507860A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
KR20130095835A (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
JP2011507859A5 (enExample)
JP2023021241A (ja) Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
US20150342986A1 (en) Compositions and methods for pain relief without numbness
Ali et al. Comparison of 5 fluorouracil and triamcinolone acetonide intralesional injection in the management of keloid
CN104736709A (zh) 基于钙粘蛋白调节的组合物和治疗
Song et al. Targeting a key pro-fibrotic factor S100A4 in cartilage to alleviate osteoarthritis progression and pain
Feldner et al. Experimental hypertension triggers varicosis‐like maladaptive venous remodeling through activator protein‐1
Lee et al. Differential effects of NADPH oxidase and xanthine oxidase inhibition on sympathetic reinnervation in postinfarct rat hearts
ES2748609T3 (es) Agonista de receptor beta-2-adrenérgico para igualar el color de las cicatrices de la piel
JP2021535925A (ja) プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ−１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用
CN114404592A (zh) Tet2作为靶标在治疗缺血性血管疾病中的应用
Huang et al. ZC3H15 suppression ameliorates bone cancer pain through inhibiting neuronal oxidative stress and microglial inflammation
KR20260051038A (ko) 조직의 성장 및 복구를 촉진하는 제품의 제조에서의 2가 금속 락테이트의 용도
US20190282600A1 (en) Combination therapies targeting tert dependency for cancer therapy
CN114788867A (zh) Map2k1作为化疗后神经痛的治疗靶点的应用
Pilichos et al. The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model
RU2499573C1 (ru) Способ лечения карбункулов почки